Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a smell test forecast brain tumor survival?

NCT ID NCT06954636

Knowledge-focused Sponsor: Sied Kebir Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 24, 2026 · Last updated Aug 25, 2026 · Updated 1 time

Summary

This study investigates whether a simple smell test could help predict survival and cognitive decline in adults newly diagnosed with glioblastoma, an aggressive brain cancer. Researchers will measure olfactory function at several points during treatment and compare it with survival data, cognitive test results, and quality-of-life measures. A control group of people without brain tumors will also take the smell test for comparison. The goal is to see if the sense of smell offers a window into how the disease may progress.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
olfactory testing (threshold and identification test)
What this could lead to
If smell function correlates with survival, it could become a simple, non-invasive tool to help gauge prognosis and guide care in glioblastoma.
What could go wrong
This is an observational study, so it cannot prove cause and effect. Results may not be definitive or change clinical practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 128 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2023

Expected to finish

Dec 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Newly-diagnosed glioblastoma

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * At least 18 years of age * Newly-diagnosed glioblastoma (IDH wild-type) * Never received prior chemotherapy * Never received radiotherapy to the head or neck before * KPS ≥ 70 * No history of severe head or brain trauma requiring ICU admission or classified as Glasgow Coma Scale grade 3 * No respiratory infection at the time of inclusion * No significant aphasia Exclusion Criteria: * Presence of Neurodegenerative diseases (e.g. Parkinson's disease, Alzheimer's disease, Huntington's disease, Korsakoff's syndrome, Pick's disease, Shy-Drager syndrome) * History of invasive tumors or surgery in the head or neck area, except for surgeries for non-invasive skin tumors (e.g. basal cell carcinomas) * Permanent olfactory impairment following infections (e.g., influenza, coronavirus) * Conditions that, in the examiner's judgment, could interfere with the participant's study compliance (e.g., schizophrenia) * Language barriers likely to interfere with participation or comprehension of study procedures.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Glioblastoma multiforme, adult are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

adult glioblastoma glioblastoma gliosarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Glioblastoma multiforme, adult Glioblastoma or gliosarcoma Glioblastoma, adult

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Department of Neurosurgery

    RECRUITING

    Münster, Germany

  • University Hospital Essen, Department of Neurology, Division of Clinical Neuro-Oncology

    RECRUITING

    Essen, 45147, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.